Track HCW Biologics Inc. Common Stock — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

HCW Biologics Inc. Common Stock HCWB · Stock Open HCW Biologics Inc. Common Stock in new tab

3.34 USD
EPS
-49.74
P/B
0.56
ROE
-27725.96
Beta
2.30
Loading chart...
Key Metrics
Earnings dateAug. 7, 2026
EPS-49.74
Book Value5.13
Price to Book0.56
Debt/Equity114.14
% Insiders9.242%
Growth
Revenue Growth1290.81%
Estimates
Forward P/E-5.18
Forward EPS-0.55

DCF Valuation

Tweak assumptions to recompute fair value for HCW Biologics Inc. Common Stock (HCWB)
Currency: USD
DCF Assumptions
Decimal (e.g., 0.10 = 10%). Range allows declines (−50%) to strong growth (+50%).
Decimal (e.g., 0.30 = 30%).
Decimal (e.g., 0.04 = 4%).
Decimal (e.g., 0.20 = 20%).
Percent number (e.g., 3 = 3%).
Percent number (e.g., 10 = 10%).
Percent number (e.g., 5 = 5%).
DCF Result

Fair Value (DCF)
Current Price
Upside
WACC
Terminal PV
Σ PV of FCFs
Note: historical bars show reported FCF (for context); forward bars show PV of projected FCF; if no per-year data, totals are shown.

HCW Biologics Inc. Common Stock Logo HCW Biologics Inc. Common Stock Analysis (HCWB)

United States Health Care Official Website Stock

Is HCW Biologics Inc. Common Stock a good investment? HCW Biologics Inc. Common Stock (HCWB) is currently trading at 3.34 USD.

Earnings Schedule: HCW Biologics Inc. Common Stock is expected to release its next earnings report on Aug. 7, 2026. The market consensus estimate for Forward EPS is -0.55.

Investor FAQ

Does HCW Biologics Inc. Common Stock pay a dividend?

No, it does not currently pay a dividend.

What asset class is HCW Biologics Inc. Common Stock?

HCW Biologics Inc. Common Stock is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.

When is the next earnings date?

The next earnings date is projected to be Aug. 7, 2026. The company currently has a trailing EPS of -49.74.

Company Profile

HCW Biologics Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and diseases in the United States. Its lead products include HCW11-018b, a novel, tetra-valent T-Cell engager; HCW11-040, a multifunctional fusion molecule that is a combination of cytokines and pembrolizumab; and HCW9302, injectable and interleukin 2 (IL-2) fusion protein complex, which is in clinical trial in patients with alopecia areata diseases. The company also develops HCW9201, a fusion protein designed as a reagent to use in the production of natural killer (NK) cell-based therapies; HCW9206, a fusion protein designed as a reagent to use in the production of CAR-therapies for the treatment of infectious diseases; and HCW11-006, a multi-functional immune cell stimulator. It has a license agreement with Wugen Inc. to develop cell therapy-based treatments; and a license, research and co-development agreement with WY Biotech Co., Ltd. for its preclinical molecule. HCW Biologics Inc. was incorporated in 2018 and is headquartered in Miramar, Florida.

Exchange Ticker
NMS (United States) HCWB
Trades
Dividend History paid per year (USD)
No dividend history available.
Stock Splits
Split Date Split Ratio to 1
April 11, 2025 0.030000
June 30, 2026 0.170000
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Fundamentals

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion